Prophylaxis, diagnosis and therapy of hepatitis-B-virus-(HBV-)infection: Upgrade of the guideline, AWMF-register 021/011;Prophylaxe, diagnostik und therapie der hepatitis-B-virus-(HBV-)infektion: "Upgrade" der leitlinie, AWMF-register-Nr.: 021/011

Zeitschrift fur Gastroenterologie

Volumn 45, Issue 6, 2007, Pages 525-574

  Cornberg, M ^a   Protzer, U ^b   Dollinger, M M ^c   Petersen, J ^d   Wedemeyer, H ^a   Berg, T ^e   Jilg, W ^f   Erhardt, A ^g   Wirth, S ^h   Schirmacher, P ⁱ   Fleig, W E ^j   Manns, Michael P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e HUMBOLDT UNIVERSITY   (Germany)

^f UNIVERSITY OF REGENSBURG   (Germany)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h UNIVERSITY OF WITTEN HERDECKE   (Germany)

ⁱ UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^j UNIVERSITY HOSPITAL LEIPZIG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

EVIDENCE BASED MEDICINE; GERMANY; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK POPULATION; HUMAN; INFECTION RISK; NONHUMAN; PERSISTENT VIRUS INFECTION; PRACTICE GUIDELINE; QUALITY CONTROL; REVIEW;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CARRIER STATE; CHILD; CHILD, PRESCHOOL; COMORBIDITY; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HEPATITIS C; HEPATITIS D; HUMANS; INFANT; INFANT, NEWBORN; INTERFERON-ALPHA; LIVER TRANSPLANTATION; PREGNANCY;

EID: 34447344085     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-963232     Document Type: Review

References (481)

1. Immunisation against hepatitis B. Lancet 1988; 1: 875-876
2. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355: 561-565
3. Ahmed A, Keeffe EB. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol 1999; 94: 249-251
4. Anandh U, Bastani B, Ballal S. Granulocyte-macrophage colony-stimulating factor as an adjuvant to hepatitis B vaccination in maintenance hemodialysis patients. Am J Nephrol 2000; 20: 53-56
5. Anselmo DM, Ghobrial RM, Jung LC et al. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002; 235: 611-619
6. Arribas JR, Gonzalez-Garcia JJ, Lorenzo A et al. Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain. AIDS 2005; 19: 1361-1365
7. Arslan M, Wiesner RH, Sievers C et al. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl 2001; 7: 314-320
8. Ascherio A, Zhang SM, Hernan MA et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001; 344: 327-332
9. Averhoff F, Mahoney F, Coleman P et al. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998; 15: 1-8
10. Awerkiew S, Daumer M, Reiser M et al. Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol 2007; 38: 83-86
11. Ayoola EA, Johnson AO. Hepatitis B vaccine in pregnancy: immunogenicity, safety and transfer of antibodies to infants. Int J Gynaecol Obstet 1987; 25: 297-301
12. Aziz A, Aziz S, Li DS et al. Efficacy of repeated high-dose hepatitis B vaccine (80 microg) in patients with chronic liver disease. J Viral Hepat 2006; 13: 217-221
13. Bae SH, Yoon SK, Choi JY et al. Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis. J Gastroenterol Hepatol 2005; 20: 1527-1532
14. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2000; 19: 877-885
15. Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006; 24: 572-577
16. Benhamou Y. Treatment algorithm for chronic hepatitis B in HIV-infected patients. J Hepatol 2006; 44: S90-S94
17. Benhamou Y, Bochet M, Thibault V et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 1302-1306
18. Benhamou Y, Thibault V, Vig P et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006; 44: 62-67
19. Benner KG, Lee RG, Keeffe EB et al. Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation. Gastroenterology 1992; 103: 1307-1312
20. Benvegnu L, Fattovich G, Noventa F et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994; 74: 2442-2448
21. Berger A, Doerr HW, Rabenau HF et al. High frequency of HCV infection in individuals with isolated antibody to hepatitis B core antigen. Intervirology 2000; 43: 71-76
22. Bienzle U, Gunther M, Neuhaus R et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003; 38: 811-819
23. Bodsworth N, Donovan B, Nightingale BN. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989; 160: 577-582
24. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991; 163: 1138-1140
25. Bortolotti F. Treatment of chronic hepatitis B in children. J Hepatol 2003; 39 (Suppl 1): S200-S205
26. Bortolotti F, Guido M, Bartolacci S et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 2006; 43: 556-562
27. Bortolotti F, Jara P, Barbera C et al. Long term effect of alpha interferon in children with chronic hepatitis B. Gut 2000; 46: 715-718
28. Brook G. Prevention of viral hepatitis in HIV co-infection. J Hepatol 2006; 44: S104-S107
29. Brook MG, Chan G, Yap I et al. Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection. BMJ 1989; 299: 652-656
30. Brook MG, McDonald JA, Karayiannis P et al. Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut 1989; 30: 1116-1122
31. Bruguera M, Rodicio JL, Alcazar JM et al. Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients. Vaccine 1990; 8 (Suppl): S47-S49
32. Brunetto MR, Oliveri F, Coco B et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263-270
33. Buti M, Jardi R, Allende H et al. Chronic delta hepatitis: is the prognosis worse when associated with hepatitis C virus and human immunodeficiency virus infections? J Med Virol 1996; 49: 66-69
34. Bzowej N, Chan HL, Lai CL et al. A randomized trial of telbivudine vs adefovir for HBeAg-positive chronic hepatitis B. Hepatology 2006; 44: 563A
35. Cacciola I, Pollicino T, Squadrito G et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-26
36. Cardell K, Fryden A, Normann B. Intradermal hepatitis B vaccination in health care workers. Response rate and experiences from vaccination in clinical practise. Scand J Infect Dis 1999; 31: 197-200
37. Caredda F, Rossi E, d'Arminio MA et al. Hepatitis B virus-associated coinfection and superinfection with delta agent: indistinguishable disease with different outcome. J Infect Dis 1985; 151: 925-928
38. Carlsson T, Struve J, Sonnerborg A et al. The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination. Scand J Infect Dis 1999; 31: 93-95
39. Castells L, Vargas V, Rodriguez F et al. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transpl 2002; 8: 892-900
40. Castelnau C, Le Gal F, Ripault MP et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006; 44: 728-735
41. CDC. Recombinant Hepatitis B Vaccine and the Risk of Multiple Sclerosis. Electronic Citation. 2004. www.cdc.gov/ncidod/diseases/hepatitis/b/ hbv_ms.pdf
42. Chalasani N, Smallwood G, Halcomb J et al. Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation? Liver Transpl Surg 1998; 4: 128-132
43. Chan HL, Leung NW, Hui AY et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142: 240-250
44. Chan HL, Tang JL, Tam W et al. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol Ther 2001; 15: 1899-1905
45. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010
46. Chang TT, Shiffman M, Tong M et al. Durability of HBeAg seroconversion after adefovir dipivoxil treatment for chronic hepatitis B (CHB). Journal of Hepatology 2004; 40: 126
47. Charest AF, McDougall J, Goldstein MB. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am J Kidney Dis 2000; 36: 976-982
48. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73
49. Chen G, Lin W, Shen F et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006; 101: 1797-1803
50. Chen JC, Chang ML, Lin JN et al. Comparison of childhood hepatic malignancies in a hepatitis B hyper-endemic area. World J Gastroenterol 2005; 11: 5289-5294
51. Chen PM, Chiou TJ, Fan FS et al. Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation. Transplantation 1999; 67: 1425-1433
52. Chen PM, Fan S, Liu CJ et al. Changing of hepatitis B virus markers in patients with bone marrow transplantation. Transplantation 1990; 49: 708-713
53. Chen YC, Sheen IS, Chu CM et al. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 123: 1084-1089
54. Cheng AL. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma. Blood 1996; 87: 1202
55. Cheng AL, Hsiung CA, Su IJ et al. Steroid-free cnemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37: 1320-1328
56. Chien RN, Yeh CT, Tsai SL et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38: 1267-1273
57. Christensen C, Bruden D, Livingston S et al. Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients. J Viral Hepat 2006; 13: 652-658
58. Chit CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006; 26: 142-152
59. Chu CM, Yeh CT, Liaw YF. Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus. Gut 1999; 45: 613-617
60. Chuang WL, Dai CY, Chang WY et al. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther 2005; 10: 125-133
61. Clark FL, Drummond MW, Chambers S et al. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 385-387
62. Clemens R, Sanger R, Kruppenbacher J et al. Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule - results of a post-marketing surveillance. Vaccine 1997; 15: 349-352
63. Coates T, Wilson R, Patrick G et al. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther 2001; 23: 392-403
64. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
65. Cohard M, Poynard T, Mathurin P et al. Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metanalysis. Hepatology 1994; 20: 1390-1398
66. Colloredo G, Bellati G, Leandro G et al. Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new "gray-zone" for the evaluation of "borderline" values. J Hepatol 1996; 25: 644-648
67. Colloredo MG, Bellati G, Leandro G et al. Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbations. Arch Virol 1993; (Suppl 8): 203-211
68. Colonno RJ, Rose R, Baldick CJ et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006; 44: 1656-1665
69. Colonno RJ, Rose RE, Pokornowski K et al. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology 2006; 44: 229A-230A
70. Confavreux C, Suissa S, Saddier P et al. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001; 344: 319-326
71. Cooksley WG. Treatment with interferons (including pegylated interferons) in patients with hepatitis B. Semin Liver Dis 2004; 24 (Suppl 1): 45-53
72. Cooksley WG, Piratvisuth T, Lee SD et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10: 298-305
73. Cortelezzi A, Vigano M, Zilioli VR et al. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J Clin Virol 2006; 35: 467-469
74. Cotonat T, Quiroga JA, Lopez-Alcorocho JM et al. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients. Hepatology 2000; 31: 502-506
75. Craxi A, Di Bona D, Camma C. Interferon-alpha for HBeAg-positive chronic hepatitis B. J Hepatol 2003; 39 (Suppl 1): S99-S105
76. Crespo J, Fabrega E, Casafont F et al. Severe clinical course of de novo hepatitis B infection after liver transplantation. Liver Transpl Surg 1999; 5: 175-183
77. Crespo J, Lozano JL, Echevarria S et al. Influence of hepatitis C virus infection and human immunodeficiency on the natural history of chronic delta hepatitis. Rev Esp Enferm Dig 1994; 85: 185-191
78. D'Antiga L, Aw M, Atkins M et al. Combined lamivudine/interferon- alpha treatment in "immunotolerant" children perinatally infected with hepatitis B: a pilot study. J Pediatr 2006; 148: 228-233
79. Dahmen A, Herzog-Hauff S, Boeder WO et al. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol 2002; 66: 452-460
80. Dai MS, Chao TY. Lamivudine therapy in HBsAg-carrying breast cancer patients undergoing chemotherapy: prophylactic or preemptive? Breast Cancer Res Treat 2005; 92: 95-96
81. Dai MS, Wu PF, Lu JJ et al. Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study. Support Care Cancer 2004; 12: 191-196
82. Davies SE, Portmann BC, O'Grady JG et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150-157
83. De Feo TM, Poli F, Mozzi F et al. Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors: a collaborative study. Transplant Proc 2005; 37: 1238-1239
84. De Maria N, Colantoni A, Friedlander L et al. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 2000; 95: 3529-3536
85. del Canho R, Grosheide PM, Mazel JA et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997; 15: 1624-1630
86. del Canho R, Grosheide PM, Voogd M et al. Immunogenicity of 20 micrograms of recombinant DNA hepatitis B vaccine in healthy neonates: a comparison of three different vaccination schemes. J Med Virol 1993; 41: 30-34
87. Delaugerre C, Marcelin AG, Thibault V et al. Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother 2002; 46: 1586-1588
88. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-69
89. Deutsch J, Wirth S. Konsensus über die Behandlung der chronischen Hepatitis B im Kindesalter. Monatsschr Kinderheilkd 2002; 150: 625-629
90. Dhedin N, Douvin C, Kuentz M et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998; 66: 616-619
91. Di Bisceglie A, Lai CL, Cane E et al. Telbivudine GLOBE trial: Maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology 2006; 44: 230A-231A
92. Di Marco V, Giacchino R, Timitilli A et al. Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study. J Viral Hepat 1996; 3: 123-128
93. Di Marco V, Marzano A, Lampertico P et al. Clinical outcome of HBe-Ag-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 883-891
94. Di Martino V, Lunel F, Cadranel JF et al. Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B. J Viral Hepat 1996; 3: 253-260
95. Di Martino V, Thevenot T, Boyer N et al. Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus-infected patients. Hepatology 2000; 31: 1030-1031
96. Di Martino V, Thevenot T, Colin JF et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002; 123: 1812-1822
97. Dickson RC, Everhart JF, Lake JR et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997; 113: 1668-1674
98. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 36: S152-S160
99. Dienstag JL. The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis B. J Hepatol 2005; 42: 158-162
100. Dienstag JL, Cianciara J, Karayalcin S et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003; 37: 748-755
101. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263
102. Dikici B, Bosnak M, Bosnak V et al. Combination therapy for children with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2002; 17: 1087-1091
103. Dikici B, Ozgenc F, Kalayci AG et al. Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter study. J Gastroenterol Hepatol 2004; 19: 127-133
104. Dore GJ, Cooper DA, Barrett C et al. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999; 180: 607-613
105. Douglas DD, Rakela J, Wright TL et al. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997; 3: 105-111
106. Duclos P. Safety of immunisation and adverse events following vaccination against hepatitis B. Expert Opin Drug Saf 2003; 2: 225-231
107. Endo T, Sakai T, Fujimoto K et al. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2001; 27: 433-436
108. Erhardt A, Blondin D, Hauck K et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54: 1009-1013
109. Erhardt A, Gerlich W, Starke C et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int 2006; 26: 805-810
110. Erhardt A, Sagir A, Guillevin L et al. Successful treatment of hepatitis B virus associated polyarteritis nodosa with a combination of prednisolone, alpha-interferon and lamivudine. J Hepatol 2000; 33: 677-683
111. Evans TG, Schiff M, Graves B et al. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination. Clin Nephrol 2000; 54: 138-142
112. Fabrizi F, Martin P, Dixit V et al. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005; 5: 2913-2921
113. Fabrizio F, Bunnapradist S, Martin P. Transplanting kidneys from donors with prior hepatitis B infection: one response to the organ shortage. J Nephrol 2002; 15: 605-613
114. Farci P, Mandas A, Coiana A et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994; 330: 88-94
115. Farci P, Roskams T, Chessa L et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004; 126: 1740-1749
116. Farci P, Smedile A, Lavarini C et al. Delta hepatitis in inapparent carriers of hepatitis B surface antigen. A disease simulating acute hepatitis B progressive to chronicity. Gastroenterology 1983; 85: 669-673
117. Farrell GC. Immunosuppression and reactivation of hepatitis B in the lamivudine era: opportunities for prevention and exploitation? J Gastroenterol Hepatol 1999; 14: 741-744
118. Fattovich G, Boscaro S, Noventa F et al. Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis 1987; 155: 931-935
119. Fattovich G, Brollo L, Boscaro S et al. Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B. J Hepatol 1989; 9: 331-337
120. Fattovich G, Giustina G, Christensen E et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000; 46: 420-426
121. Firpi RJ, Nelson DR. Viral hepatitis: manifestations and management strategy. Hematology Am Soc Hematol Educ Program 2006: 375-380
122. Flink HJ, van Zonneveld M, Hansen BE et al. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101: 297-303
123. Floreani A, Boninsegna S, Lobello S et al. Fatal hepatic decompensation in a bone marrow transplant recipient with HBV-related citrhosis following lamivudine withdrawal. Gastroenterol Clin Biol 2006; 30: 307-309
124. Fontana RJ, Hann HW, Perrillo RP et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 719-727
125. Fontana RJ, Keeffe EB, Carey W et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002; 8: 433-439
126. Fornairon S, Pol S, Legendre C et al. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 1996; 62: 297-299
127. Fouillard L, Serfaty L, Gozlan J. Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 37: 625-626
128. Fukuda R, Ishimura N, Kushiyama Y et al. Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver. J Hepatol 1997; 26: 455-461
129. Fung SK, Chae HB, Fontana RJ et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283-290
130. Fung SK, Wong F, Hussain M et al. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004; 11: 432-438
131. Fytili P, Ciesek S, Manns MP et al. Anti-HBc seroconversion after transplantation of anti-HBc positive nonliver organs to anti-HBc negative recipients. Transplantation 2006; 81: 808-809
132. Gan SI, Devlin SM, Scott-Douglas NW et al. Lamivudine for the treatment of membranous glomerulopathy secondary to chronic Hepatitis B infection. Can J Gastroenterol 2005; 19: 625-629
133. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002; 74: 427-437
134. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129
135. Garripoli A, Di Marco V, Cozzolongo R et al. Ribavirin treatment for chronic hepatitis D: a pilot study. Liver 1994; 14: 154-157
136. Gaudin JL, Trepo C. Therapy of chronic delta hepatitis with alpha- and beta-interferon. Prog Clin Biol Res 1993; 382: 345-352
137. Geier MR, Geier DA. Immunologic reactions and hepatitis B vaccine. Ann Intern Med 2001; 134: 1155
138. Gerlich WH, Thomssen R. Terminology, structure and laboratory diagnosis of hepatitis viruses. In: Bircher J, Benhamou JP, McIntyre N, Rizetto M, Rhodes J (Hrsg). Oxford Textbook of Clinical Hepatology. Oxford: Oxford University press, 1999: 828-869
139. Ghany MG, Ayola B, Villamil FG et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27: 213-222
140. Gigliotti AR, Fioredda F, Giacchino R. Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation. J Pediatr Hematol Oncol 2003; 25: 184-192
141. Girard M. Autoimmune hazards of hepatitis B vaccine. Autoimmun Rev 2005; 4: 96-100
142. Gish RG, Chang TT, de Man RA et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022). Hepatology 2005; 42: 267A-268A
143. Govindarajan S, Chin KP, Redeker AG et al. Fulminant B viral hepatitis: role of delta agent. Gastroenterology 1984; 86: 1417-1420
144. Gregorio GV, Jara P, Hierro L et al. Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial. Hepatology 1996; 23: 700-707
145. Grob P, Jilg W, Bornhak H et al. Serological pattern "anti-HBc alone": report on a workshop. J Med Virol 2000; 62: 450-455
146. Gunsar F, Akarca US, Ersoz G et al. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther 2005; 10: 721-726
147. Hadler SC, Alcala DM, Rivero D et al. Epidemiology and long-term consequences of hepatitis delta virus infection in the Yucpa Indians of Venezuela. Am J Epidemiol 1992; 136: 1507-1516
148. Hadler SC, de Monzon M, Ponzetto A et al. Delta virus infection and severe hepatitis. An epidemic in the Yucpa Indians of Venezuela. Ann Intern Med 1984; 100: 339-344
149. Hadler SC, Francis DP, Maynard JE et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315: 209-214
150. Hadler SC, Judson FN, O'Malley PM et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991; 163: 454-459
151. Hadziyannis SJ, Papatheodoridis GV, Dimou E et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847-851
152. Hadziyannis SJ, Sevastianos V, Rapti I et al. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil treatment in HBeAg-negative chronic hepatitis B. Hepatology 2006; 44: 231A
153. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 2673-2681
154. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years. Gastroenterology 2006; 131: 1743-1751
155. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-807
156. Hartman C, Berkowitz D, Eshach-Adiv O et al. Long-term lamivudine therapy for chronic hepatitis B infection in children unresponsive to interferon. J Pediatr Gastroenterol Nutr 2006; 43: 494-498
157. Hartwig MG, Patel V, Palmer SM et al. Hepatitis B core antibody positive donors as a safe and effective therapeutic option to increase available organs for lung transplantation. Transplantation 2005; 80: 320-325
158. Hasselhorn HM, Kralj N, Hofmann F et al. Non- and low-response after preventive hepatitis B vaccination. Gesundheitswesen 1997; 59: 321-328
159. Heintges T, Petry W, Kaldewey M et al. Combination therapy of active HBsAg vaccination and interferon-alpha in interferon-alpha nonresponders with chronic hepatitis B. Dig Dis Sci 2001; 46: 901-906
160. Henderson EA, Louie TJ, Ramotar K et al. Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers. Infect Control Hosp Epidemiol 2000; 21: 264-269
161. Hernan MA, Jick SS, Olek MJ et al. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 2004; 63: 838-842
162. Hillis WD, Hillis A, Walker WG. Hepatitis B surface antigenemia in renal transplant recipients. Increased mortality risk. JAMA 1979; 242: 329-332
163. Hoff J, Bani-Sadr F, Gassin M et al. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis 2001; 32: 963-969
164. Horn X, Little NR, Gardner SD et al. Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection. Pediatr Infect Dis J 2004; 23: 441-445
165. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355: 2444-2451
166. Housset C, Pol S, Carnot F et al. Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus. Hepatology 1992; 15: 578-583
167. Hsu YS, Chien RN, Yeh CT et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-1527
168. Hui AY, Chan HL, Cheung AY et al. Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther 2005; 22: 519-528
169. Hui CK, Cheung WW, Au WY et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005; 54: 1597-1603
170. Hui CK, Cheung WW, Zhang HY et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68
171. Hui CK, Lau E, Wu H et al. Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection. J Clin Virol 2006; 35: 185-192
172. Huo TI, Wu JC, Lai CR et al. Comparison of clinico-pathological features in hepatitis B virus-associated hepatocellular carcinoma with or without hepatitis D virus superinfection. J Hepatol 1996; 25: 439-444
173. Iannitto E, Minardi V, Calvaruso G et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 2005; 74: 254-258
174. Idilman R, Arat M, Soydan E et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 2004; 11: 141-147
175. Idilman R, Colantoni A, De Maria N et al. Impaired antibody response rates after high dose short interval hepatitis B virus vaccination of immunosuppressed individuals. Hepatogastroenterology 2003; 50: 217-221
176. Ikeda K, Shiga Y, Takahashi A et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma 2006; 47: 155-157
177. Han Y, Ashur Y, Tur-Kaspa R et al. Chronic hepatitis C virus infection with exposure to hepatitis B virus. Isr J Med Sci 1994; 30: 259-263
178. Iloeje UH, Yang HI, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686
179. Imbert-Bismut F, Ratziu V, Pieroni L et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-1075
180. Institute of Medicine - Report. Hepatitis B vaccine and demyelinating neurological disorders. Electronic Citation. 2002. www.cdc.gov/nip/ vaccine/hep/hepb/iom.htm
181. Iwai K, Tashima M, Itoh M et al. Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period. Bone Marrow Transplant 2000; 25: 105-108
182. Jang JW, Choi JY, Bae SH et al. Transarterial chemo- lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol 2004; 41: 427-435
183. Jang JW, Choi JY, Bae SH et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006; 43: 233-240
184. Janssen HL, van Zonneveld M, Senfurk H et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-129
185. Janssen HL, van Zonneveld M, van Nunen AB et al. Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome. Eur J Gastroenterol Hepatol 2004; 16: 801-807
186. Jardi R, Rodriguez F, Buti M et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral implicative interference. Hepatology 2001; 34: 404-410
187. Jilg W, Hottentrager B, Weinberger K et al. Prevalence of markers of hepatitis B in the adult German population. J Med Virol 2001; 63: 96-102
188. Jilg W, Schmidt M, Deinhardt F. Four-year experience with a recombinant hepatitis B vaccine. Infection 1989; 17: 70-76
189. Jilg W, Schmidt M, Deinhardt F. Inoculation failure following hepatitis B vaccination. The effect of additional vaccinations. Dtsch Med Wochenschr 1990; 115: 1545-1548
190. Jonas MM, Mizerski J, Badia IB et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002; 346: 1706-1713
191. Kanaan N, Horsmans Y, Coffin E. Lamivudine for nephrotic syndrome related to hepatitis B virus (HBV) infection. Clin Nephrol 2006; 65: 208-210
192. Kanwal F, Farid M, Martin P et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol 2006; 101: 2076-2089
193. Kapoor D, Aggarwal SR, Singh NP et al. Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients. J Viral Hepat 1999; 6: 405-409
194. Kapoor D, Guptan RC, Wakit SM et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000; 33: 308-312
195. Kelly D. Viral hepatitis in children. Adv Exp Med Biol 2004; 549: 83-90
196. Kempinska A, Kwak EJ, Angel JB. Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. Clin Infect Dis 2005; 41: 1277-1182
197. Kim KH, Ahn SH, Chung HY et al. Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity. J Gastroenterol Hepatol 2004; 19: 847-853
198. Knoll A, Boehm S, Hahn J et al. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 33: 925-929
199. Knoll A, Hartmann A, Hamoshi H et al. Serological pattern "anti-HBc alone": characterization of 552 individuals and clinical significance. World J Gastroenterol 2006; 12: 1255-1260
200. Kohmoto M, Enomoto M, Tamori A et al. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol 2005; 75: 235-239
201. Kondili LA, Osman H, Mutimer D. The use of lamivudine for patients with acute hepatitis B (a series of cases). J Viral Hepat 2004; 11: 427-431
202. Konopnicki D, Mocroft A, de Wit S et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593-601
203. Korenman J, Baker B, Waggoner J et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114: 629-634
204. Kruger M, Boker KH, Zeidler H et al. Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b. J Hepatol 1997; 26: 935-939
205. Kumagai K, Takagi T, Nakamura S et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997; 8 (Suppl 1): 107-109
206. Kumar M, Satapathy S, Monga R et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007; 45: 97-101
207. Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004; 2: 266-272
208. Lackner H, Moser A, Benesch M et al. Serological and molecular response on combined antiviral treatment in children with chronic hepatitis B after pediatric malignancy. J Clin Virol 2002; 25 (Suppl 3): S73-S79
209. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68
210. Lai CL, Dienstag J, Schiff E et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-696
211. Lai CL, Gone E, Hsu CW et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine vs lamivudine. Hepatology 2006; 44: 222A
212. Lai CL, Gane E, Liaw YF et al. Telbivudine (LdT) vs. lamivudine for chronic hepatitis B: First-year results from the international phase III globe trial. Hepatology 2005; 42: 748A
213. Lai CL, Leung N, Teo EK et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528-536
214. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020
215. Lampertico P, Del Ninno E, Vigano M et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003; 37: 756-763
216. Lampertico P, Marzano A, Levrero M et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. Hepatology 2006; 44: 693A-694A
217. Lampertico P, Vigano M, Manenti E et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 1414-1419
218. Lang M, Neumann U, Kahl A et al. Long-term outcome of 27 patients after combined liver-kidney transplantation. Transplant Proc 2001; 33: 1440-1441
219. Lau DT, Doo E, Park Y et al. Lamivudine for chronic delta hepatitis. Hepatology 1999; 30: 546-549
220. Lau DT, Everhart J, Kleiner DE et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113: 1660-1667
221. Lau DT, Kleiner DE, Park Y et al. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology 1999; 117: 1229-1233
222. Lau GK, He ML, Fong DY et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002; 36: 702-709
223. Lau GK, Liang R, Chiu EK et al. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplant 1997; 19: 795-799
224. Lau GK, Lok AS, Liang RH et al. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology 1997; 25: 1497-1501
225. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695
226. Lau GK, Suri D, Liang R et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002; 122: 614-624
227. Lau GK, Yiu HH, Fong DY et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-1749
228. Lau JY, Smith HM, Chaggar K et al. Significance of IgM anti-hepatitis D virus (HDV) in chronic HDV infection. J Med Virol 1991; 33: 273-276
229. Laubscher B, Gehri M, Roulet M et al. Survival of infantile fulminant hepatitis B and treatment with Lamivudine. J Pediatr Gastroenterol Nutr 2005; 40: 518-520
230. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107
231. Law JK, Ho JK, Hoskins PJ et al. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005; 46: 1085-1089
232. Le Gal F, Gordien E, Affolabi D et al. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. J Clin Microbiol 2005; 43: 2363-2369
233. Leaw SJ, Yen CJ, Huang WT et al. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 2004; 83: 270-275
234. Lee C, Gong Y, Brok J et al. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 2006; 332: 328-336
235. Lee C, Gong Y, Brok J et al. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev CD004790 2006
236. Lee GW, Ryu MH, Lee JL et al. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci 2003; 18: 849-854
237. Lee KM, Cho SW, Kim SW et al. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002; 9: 208-212
238. Lee WC, Wu MJ, Cheng CH et al. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am J Kidney Dis 2001; 38: 1074-1081
239. Lee YS, Suh DJ, Lim YS et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43: 1385-1391
240. Li YH, He YF, Jiang WQ et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006; 106: 1320-1325
241. Liao SS, Li RC, Li H et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine 1999; 17: 2661-2666
242. Liaw YF. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma. Semin Liver Dis 2005; 25 (Suppl 1): 40-47
243. Liaw YF, Chen YC, Sheen IS et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004; 126: 1024-1029
244. Liaw YF, Chien RN, Yeh CT. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther 2004; 9: 257-262
245. Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-180
246. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531
247. Liaw YF, Tsai SL, Sheen IS et al. Clinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers. Am J Gastroenterol 1998; 93: 354-359
248. Lim LL, Wai CT, Lee YM et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 2002; 16: 1939-1944
249. Lim SG, Krastev Z, Ng TM et al. Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. Antimicrob Agents Chemother 2006; 50: 1642-1648
250. Lin CC, Chen CL, Concejero A et al. Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients. Am J Transplant 2007; 7: 195-200
251. Lin SM, Sheen IS, Chien RN et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-975
252. Lin SM, Yu ML, Lee CM et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46: 45-52
253. Lo CM, Liu CL, Lau GK et al. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005; 11: 807-813
254. Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2005; 25 (Suppl 1): 9-19
255. Locarnini S, Hatzakis A, Heathcote J et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004; 9: 679-693
256. Lok AS, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988; 8: 1130-1133
257. Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-1722
258. Lok AS, Liang RH, Chiu EK et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-188
259. Lok AS, McMahon BJ. AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines. Rom J Gastroenterol 2004; 13: 150-154
260. Looney RJ, Hasan MS, Coffin D et al. Hepatitis B immunization of healthy elderly adults: relationship between naive CD4+ T cells and primary immune response and evaluation of GM-CSF as an adjuvant. J Clin Immunol 2001; 21: 30-36
261. Lucey MR, Graham DM, Martin P et al. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut 1992; 33: 1390-1396
262. Madejon A, Cotonat T, Bartolome J et al. Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: utility of polymerase chain reaction in monitoring antiviral response. Hepatology 1994; 19: 1331-1336
263. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121: 101-109
264. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55: 1350-1359
265. Manzarbeitia C, Reich DJ, Ortiz JA et al. Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl 2002; 8: 556-561
266. Marangi AL, Giordano R, Montanaro A et al. Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination. Am J Kidney Dis 1994; 23: 537-542
267. Marcellin P, Boyer N, Colin JF et al. Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine. Gut 1993; 34: S106
268. Marcellin P, Chang TT, Lim SG et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B (CHB) patients. Hepatology 2006; 44: 548A
269. Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816
270. Marcellin P, Lau GK, Bonino F et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217
271. Margreiter R, Kramar R, Huber C et al. Combined liver and kidney transplantation. Lancet 1984; 1: 1077-1078
272. Maria Elzbieta SL, Marek LD. Histological outcome of chronic hepatitis B in children treated with interferon alpha. World J Gastroenterol 2005; 11: 7179-7182
273. Markovic S, Drozina G, Vovk M et al. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepato-gastroenterology 1999; 46: 2925-2930
274. Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-589
275. Martinez E, Blanco JL, Arnaiz JA et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15: 1261-1268
276. Marusawa H, Chiba T. How can we prevent viral reactivation in liver transplantation from donors with latent hepatitis B virus infection? J Gastroenterol 2001; 36: 212-213
277. Marzano A, Salizzoni M, Debernardi-Venon W et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 903-910
278. Mason WS, Taylor JM. Liver transplantation: a model for the transmission of hepatitis delta virus. Gastroenterology 1991; 101: 1741-1743
279. Mast EE, Weinbaum CM, Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55: 1-33
280. Mathurin P, Mouquet C, Poynard T et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-263
281. Mathurin P, Thibault V, Kadidja K et al. Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections. J Viral Hepat 2000; 7: 15-22
282. McDonald JA, Harris S, Waters JA et al. Effect of human immunodeficiency virus (HIV) infection on chronic hepatitis B hepatic viral antigen display. J Hepatol 1987; 4: 337-342
283. McMahon BJ, Alward WL, Hall DB et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 151: 599-603
284. Mertens T, Haller OA, Klenk HD. Diagnostik und Therapie von Virus-krankheiten: Leitlinien der Gesellschaft für Virologie. München: Urban und Fischer-Verlag, 2004
285. Mettang T, Schenk U, Thomas S et al. Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure. A preliminary study. Nephron 1996; 72: 192-196
286. Miro JM, Laguno M, Moreno A et al. Management of end stage liver disease (ESLD): what is the current role of orthotopic liver transplantation (OUT)? J Hepatol 2006; 44: S140-S145
287. Mitsui T, Iwano K, Suzuki S et al. Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: comparison with immune globulin without vaccine in historical controls. Hepatology 1989; 10: 324-327
288. Mitwalli A. Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. Nephron 1996; 73: 417-420
289. Monteyne P, Andre FE. Is there a causal link between hepatitis B vaccination and multiple sclerosis? Vaccine 2000; 18: 1994-2001
290. Mutchnick MG, Lindsay KL, Schiff ER et al. Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. J Viral Hepat 1999; 6: 397-403
291. Myers RP, Tainturier MH, Ratziu V et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003; 39: 222-230
292. Nagamatsu H, Itano S, Nagaoka S et al. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol 2004; 99: 2369-2375
293. Nagamatsu H, Kumashiro R, Itano S et al. Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC. Hepatol Res 2003; 26: 293-301
294. Nakamura Y, Motokura T, Fujita A et al. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 1996; 78: 2210-2215
295. Neff GW, Bonham A, Tzakis AG et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9: 239-247
296. Neff GW, Nery J, Lau DT et al. Tenofovir therapy for lamivudine resistance following liver ttansplantation. Ann Pharmacother 2004; 38: 1999-2004
297. Neumann UP, Lang M, Moldenhauer A et al. Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation. Transplantation 2001; 71: 1163-1168
298. Ni YH, Huang FC, Wu TC et al. Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection patients. Pediatr Int 2005; 47: 372-377
299. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-1427
300. Niro GA, Ciancio A, Gaeta GB et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006; 44: 713-720
301. Ohtsu T, Sai T, Oka M et al. Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies. Jpn J Clin Oncol 1991; 21: 360-365
302. Olausson M, Mjornstedt L, Norden G et al. Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross-match positive recipients. Am J Transplant 2007; 7: 130-136
303. Ollenschlager G, Kopp I, Lelgemann M et al. The German program for disease management guidelines. Background, methods, and development process. Med Klin (Munich) 2006; 101: 840-845
304. Onozawa M, Hashino S, Izumiyama K et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005; 79: 616-619
305. Ozgenc F, Arikan C, Sertoz RY et al. Effect of long-tetm lamivudine in chronic hepatitis B virus-infected children. Antivir Ther 2004; 9: 729-732
306. Ozguroglu M, Bilki A, Turna H et al. Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma. Med Oncol 2004; 21: 67-72
307. Palmer DR, Perry KR, Mortimer PP et al. Variation in the sensitivity of HBsAg screening kits. Transfus Med 1996; 6: 311-317
308. Papatheodoridis GV, Dimou E, Laras A et al. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36: 219-226
309. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBe-Ag-negative chronic hepatitis B. J Hepatol 2001; 34: 306-313
310. Park JW, Park KW, Cho SH et al. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study. Am J Gastroenterol 2005; 100: 2194-2200
311. Pastore G, Santantonio T, Monno L et al. Permanent inhibition of viral replication induced by low dosage of human leukocyte interferon in patients with chronic hepatitis B. Hepatogastroenterology 1988; 35: 57-61
312. Perrillo R, Hann HW, Mutimer D et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90
313. Perrillo RP, Lai CL, Liaw YF et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186-194
314. Perrillo RP, Wright T, Rakela J et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33: 424-432
315. Persico M, De Marino F, Russo GD et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002; 99: 724-725
316. Perz JF, Armstrong GL, Farrington LA et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538
317. Peters MG, Andersen J, Lynch P et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006; 44: 1110-1116
318. Peters MG, Hann HH, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101
319. Pineda JA, Romero-Gomez M, Diaz-Garcia F et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005; 41: 779-789
320. Pirson Y, Alexandre GP, Ypersele C. Long-term effect of HBs antigenemia on patient survival after renal transplantation. N Engl J Med 1977; 296: 194-196
321. Poge U, Gerhardt T, Palmedo H et al. MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant 2005; 5: 1306-1311
322. Pol S, Wesenfelder L, Dubois F et al. Influence of human immunodeficiency virus infection on hepatitis delta virus superinfection in chronic HBsAg carriers. J Viral Hepat 1994; 1: 131-137
323. Pollicino T, Squadrito G, Cerenzia G et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126: 102-110
324. Pontisso P, Ruvoletto MG, Fattovich G et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 1993; 105: 1529-1533
325. Poynard T, Zoulim F, Ratziu V et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005; 100: 1970-1980
326. Prakoso E, Strasser SI, Koorey DJ et al. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. Clin Transplant 2006; 20: 369-373
327. Pramoolsinsap C, Poovorawan Y, Hirsch P et al. Acute, hepatitis-A super-infection in HBV carriers, or chronic liver disease related to HBV or HCV. Ann Trop Med Parasitol 1999; 93: 745-751
328. Prieto M, Gomez MD, Berenguer M et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001; 7: 51-58
329. Propst T, Propst A, Lhotta K et al. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis 1998; 32: 1041-1045
330. Protzer-Knolle U, Naumann U, Bartenschlager R et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27: 254-263
331. Puoti M, Airoldi M, Bruno R et al. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev 2002; 4: 27-35
332. Puoti M, Cozzi-Lepri A, Arid C et al. Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. Antivir Ther 2006; 11: 567-574
333. Puoti M, Tortl C, Bruno R et al. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006; 44: S65-S70
334. Ragni MV, Belle SH, Im K et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188: 1412-1420
335. Ragni MV, Eghtesad B, Schlesinger KW et al. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl 2005; 11: 1425-1430
336. Rahman F, Dahmen A, Herzog-Hauff S et al. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 2000; 31: 521-527
337. Raimondo G, Pollicino T, Cacciola I et al. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-170
338. Ranger-Rogez S, Denis F. Hepatitis B mother-to-child transmission. Expert Rev Anti Infect Ther 2004; 2: 133-145
339. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-229
340. Rendi-Wagner P, Wiedemann G, Stemberger H et al. New vaccination strategies for low- and non-responders to hepatitis B vaccine. Wien Klin Wochenschr 2002; 114: 175-180
341. Resti M, Azzari C, Mannelli F et al. Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections indicated? Vaccine 1997; 15: 1338-1340
342. Rizzetto M. Hepatitis D: virology, clinical and epidemiological aspects. Acta Gastroenterol Belg 2000; 63: 221-224
343. Rizzetto M. Hepatitis delta: the virus and the disease. J Hepatol 1990; 11 (Suppl 1): S145-S148
344. Rizzetto M, Macagno S, Chiaberge E et al. Liver transplantation in hepatitis delta virus disease. Lancet 1987; 2: 469-471
345. Rizzetto M, Verme G, Recchia S et al. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med 1983; 98: 437-441
346. Robert Koch-Institut. Zur Situation wichtiger Infektionskrankheiten in Deutschland: Virushepatitis B, C und D im Jahr 2005. Epidem Bull 2006; 46
347. Robert Koch-Institut. Mitteilungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Hinweise für Ärzte zum Aufklärungsbedarf bei Schutzimpfungen. Epidem Bull 2004; 6: 33-52
348. Robert Koch-Institut. Virushepatitis B, C und D im Jahre 2004. Epidem Bull 2005; 46: 421-236
349. Robert Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand Juli 2006. Epidem Bull 2006; 30: 235-254
350. Roche B, Samuel D, Gigou M et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997; 26: 517-526
351. Rockstroh JK. Influence of viral hepatitis on HIV infection. J Hepatol 2006; 44: S25-S27
352. Rodella A, Galli C, Terlenghi L et al. Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol 2006; 37: 206-212
353. Romand F, Michallet M, Pichoud C et al. Hepatitis B virus reactivation after allogeneic bone marrow transplantation in a patient previously cured of hepatitis B. Gastroenterol Clin Biol 1999; 23: 770-774
354. Roque-Afonso AM, Feray C, Samuel D et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002; 50: 95-99
355. Rosenau J, Bahr MJ, Tillmann HL et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895-902
356. Rosenau J, Hooman N, Rifai K et al. Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. Transpl Int 2006; 19: 828-833
357. Rosina F, Pintus C, Meschievitz C et al. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology 1991; 13: 1052-1056
358. Rosina F, Rizzetto M. Treatment of chronic type D (delta) hepatitis with alpha interferon. Semin Liver Dis 1989; 9: 264-266
359. Rosman AS, Basu P, Galvin K et al. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. Am J Med 1997; 103: 217-222
360. Rossi G, Pelizzari A, Motta M et al. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAG carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001; 115: 58-62
361. Ruiz R, Kunitake H, Wilkinson AH et al. Long-term analysis of combined liver and kidney transplantation at a single center. Arch Surg 2006; 141: 735-741
362. Ryu SH, Chung YH, Choi MH et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol 2003; 39: 614-619
363. Sadovnick AD, Scheifele DW. School-based hepatitis B vaccination programme and adolescent multiple sclerosis. Lancet 2000; 355: 549-550
364. Sagnelli E, Coppola N, Scolastico C et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology 2000; 32: 1106-1110
365. Sagnelll E, Pasquale G, Coppola N et al. Influence of chronic coinfection with hepatitis B and C virus on liver histology. Infection 2004; 32: 144-148
366. Sakallioglu O, Gok F, Kalman S et al. Hepatitis B complicated focal segmental glomerulosclerosis. J Nephrol 2005; 18: 433-435
367. Saltik-Temizel IN, Kocak N, Demir H. Interferon-alpha and lamivudine combination therapy of children with chronic hepatitis b infection who were interferon-alpha nonresponders. Pediatr Infect Dis J 2004; 23: 466-468
368. Saltik-Temizel IN, Kocak N, Demir H. Lamivudine and high-dose interferon-alpha combination therapy for naive children with chronic hepatitis B infection. J Clin Gastroenterol 2005; 39: 68-70
369. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847
370. Samuel D, Zignego AL, Reynes M et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 1995; 21: 333-339
371. Sanchez-Fueyo A, Rimola A, Grande L et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31: 496-501
372. Saracco G, Rosina F, Brunetto MR et al. Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection. J Hepatol 1987; 5: 274-281
373. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005; 11: 189-191
374. Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 2005; 23: 3876-3886
375. Scheiblauer H, Soboll H, Nick S. Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection. J Med Virol 2006; 78 (Suppl 1): S66-S70
376. Schiff ER, Lai CL, Hadziyannis S et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 1419-1427
377. Schildgen O, Sirma H, Funk A et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006; 354: 1807-1812
378. Schirmacher P, Fleig WE, Tannapfel A et al. Bioptic diagnosis of chronic hepatitis. Results of an evidence-based consensus conference of the German Society of Pathology, of the German Society for Digestive and Metabolic Diseases and of Compensated Hepatitis (HepNet). Pathologe 2004; 25: 337-348
379. Schmilovitz-Weiss H, Ben Ari Z, Sikuler E et al. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int 2004; 24: 547-551
380. Schmutz G, Nelson M, Lutz T et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006; 20: 1951-1954
381. Seaworth B, Drucker J, Starling J et al. Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis 1988; 157: 332-337
382. Segovia R, Sanchez-Fueyo A, Rimola A et al. Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation. Liver Transpl 2001; 7: 106-112
383. Seth P, Alrajhi AA, Kagevi I et al. Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant 2002; 30: 189-194
384. Shattock AG, Morris MC. Evaluation of commercial enzyme immunoassays for detection of hepatitis delta antigen and anti-hepatitis delta virus (HDV) and immunoglobulin M anti-HDV antibodies. J Clin Microbiol 1991; 29: 1873-1876
385. Sheldon J, Camino N, Rodes B et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10: 727-734
386. Sheldon JA, Corral A, Rodes B et al. Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS 2005; 19: 2036-2038
387. Sheng WH, Hung CC, Kao JH et al. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study. Clin Infect Dis 2007; 44: 988-995
388. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22: 432-438
389. Sherman M, Yurdaydin C, Sollano J et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039-2049
390. Shibolet O, Ilan Y, Gillis S et al. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002; 100: 391-396
391. Silvestri F, Sperotto A, Ermacora A et al. Lamivudine for the prevention of hepatitis B virus reactivation during autologous stem cell transplantation. A case report. Haematologica 2000; 85: 327-329
392. Smedile A, Farci P, Verme G et al. Influence of delta infection on severity of hepatitis B. Lancet 1982; 2: 945-947
393. Sokal E. Drug treatment of pediatric chronic hepatitis B. Paediatr Drugs 2002; 4: 361-369
394. Sokal EM, Kelly DA, Mizerski J et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology 2006; 43: 225-232
395. Soriano V, Barreiro P, Nunez M. Management of chronic hepatitis B and C in HIV-coinfected patients. J Antimicrob Chemother 2006; 57: 815-818
396. Soriano V, Puoti M, Bonacini M et al. Care of patients with chronic hepatitis B and HIV co-infection; recommendations from an HIV-HBV International Panel. AIDS 2005; 19: 221-240
397. Spengler U, Lichterfeld M, Rockstroh JK. Antiretroviral drug toxicity - a challenge for the hepatologist? J Hepatol 2002; 36: 283-294
398. Sponseller CA, Bacon BR, Di Bisceglie AM. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine. Liver Transpl 2000; 6: 715-720
399. Starkel P, Stoffel M, Lerut J et al. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients. Liver Transpl 2005; 11: 1228-1234
400. Steinmuller T, Seehofer D, Rayes N et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 1528-1535
401. Stevens CE, Alter HJ, Taylor PE et al. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 1984; 311: 496-501
402. Su CW, Huang YH, Huo TI et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology 2006; 130: 1625-1635
403. Su GG, Pan KH, Zhao NF et al. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol 2004; 10: 910-912
404. Sung JJY, Lai JY, Zeuzem S et al. A randomised double-blind phase II study of lamivudine (LAM) compated to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): Week 52 analysis. Journal of Hepatology 2003; 38: 25-26
405. Tabor E. Infections by hepatitis B surface antigen gene mutants in Europe and North America. J Med Virol 2006; 78 (Suppl 1): S43-S47
406. Tang JR, Cova L, Lamelin JP et al. Clinical relevance of the detection of hepatitis delta virus RNA in serum by RNA hybridization and polymerase chain reaction. J Hepatol 1994; 21: 953-960
407. Tassopoulos NC, Papaevangelou GJ, Sjogren MH et al. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 1987; 92: 1844-1850
408. Tenderich G, Zittermann A, Prohaska W et al. Frequent detection of hepatitis B core antibodies in heart transplant recipients without preceding hepatitis B infection. Transplant Proc 2005; 37: 4522-4524
409. Tenney D, Baldick CJ, Rose RE et al. Only a subset of HBV substitutions at entecavir resistance residues lead to phenotypic resistance and virologic rebound. Hepatology 2006; 44: 253A-254A
410. ter Borg F, Smorenburg S, de Man RA et al. Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy. Dig Dis Sci 1998; 43: 2267-2270
411. Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl 2005; 11: 716-732
412. Thierfelder W, Hellenbrand W, Meisel H et al. Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998. Eur J Epidemiol 2001; 17: 429-435
413. Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis 2003; 23: 125-136
414. Thio CL, Seaberg EC, Skolasky RJr et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-1926
415. Thomas HC, Lemon S, Zuckerman AJ. Viral Hepatitis. In: Thomas HC, Lemon S, Zuckerman AJ (Hrsg). Blackwell Publishing 2005
416. Tillmann HL, Hadem J, Leifeld L et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006; 13: 256-263
417. Tseng PL, Lu SN, Tung HD et al. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. J Viral Hepat 2005; 12: 386-392
418. Tsutsumi Y, Tanaka J, Kawamura T et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004; 83: 58-60
419. Uemoto S, Inomata Y, Sannomiya A et al. Posttransplant hepatitis B infection in liver transplantation with hepatitis B core antibody-positive donors. Transplant Proc 1998; 30: 134-135
420. van Bommel F, Wunsche T, Mauss S et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40: 1421-1425
421. van Bommel F, Zoltner B, Sarrazin C et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44: 318-325
422. Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board. BMJ 1997; 314: 1033-1036
423. van Nunen AB, Hansen BE, Suh DJ et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52: 420-424
424. van Zonneveld M, van Nunen AB, Niesters HG et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003; 10: 294-297
425. Vassiliadis T, Garipidou V, Tziomalos K et al. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy - a prospective case series. Am J Hematol 2005; 80: 197-203
426. Verme G, Brunetto MR, Oliveri F et al. Role of hepatitis delta virus infection in hepatocellular carcinoma. Dig Dis Sci 1991; 36: 1134-1136
427. Villa E, Grottola A, Buttafoco P et al. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol 2001; 96: 2973-2977
428. Villeneuve E, Vincelette J, Villeneuve JP. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol 2000; 14 (Suppl B): 59B-62B
429. Villeneuve JP, Condreay LD, Willems B et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207-210
430. Villeneuve JP, Durantel D, Durantel S et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39: 1085-1089
431. Vo Thi DH, Bourgois A, Bontems P et al. Chronic hepatitis B infection: long term comparison of children receiving interferon alpha and untreated controls. J Pediatr Gastroenterol Nutr 2005; 40: 141-145
432. Wai CT, Chu CJ, Hussain M et al. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002; 36: 1425-1430
433. Wainwright RB, Bulkow LR, Parkinson AJ et al. Protection provided by hepatitis B vaccine in a Yupik Eskimo population - results of a 10-year study. J Infect Dis 1997; 175: 674-677
434. Waked I, Amin M, Abd EF et al. Experience with intetferon in chronic hepatitis B in Egypt. J Chemother 1990; 2: 310-318
435. Walker UA, Bauerle J, Laguno M et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004; 39: 311-317
436. Walter J, Radun D, Claus H et al. Hepatitis B and C risk factors in Germany - results of the national surveillance. Gesundheitswesen 2005; 67: 441-447
437. Wands JR, Chura CM, Roll FJ et al. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975; 68: 105-112
438. Wartelle-Bladou C, Lafon J, Trepo C et al. Successful combination therapy of polyarteritis nodosa associated with a pre-core promoter mutant hepatitis B virus infection. J Hepatol 2001; 34: 774-779
439. Watson B, West DJ, Chilkatowsky A et al. Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine. Vaccine 2001; 19: 3164-3168
440. Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol 2005; 32: 102-112
441. Wedemeyer H, Cornberg M, Tegtmeyer B et al. Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with hepatitis C virus replication. Clin Microbiol Infect 2004; 10: 70-72
442. Weltman MD, Brotodihardjo A, Crewe EB et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995; 2: 39-45
443. Wen YK, Chen ML. Remission of hepatitis B virus-associated membranoproliferative glomerulonephritis in a cirrhotic patient after lamivudine therapy. Clin Nephrol 2006; 65: 211-215
444. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996; 14: 1019-1027
445. Westhoff TH, Jochimsen F, Schmittet A et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930
446. Westland C, Delaney W, Yang H et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxill. Gastroenterology 2003; 125: 107-116
447. Westland CE, Yang H, Delaney WE et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003; 38: 96-103
448. Whittle H, Jaffar S, Wansbrough M et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 2002; 325: 569
449. Wiegand J, Hasenclever D, Tillman HL. Should treatment of hepatitis B depend on HBV genotypes? - A hypothesis generated from an explorative analysis of published evidence. Hepatology 2006; 44: 564A-565A
450. Williams R. Global challenges in liver disease. Hepatology 2006; 44: 521-526
451. Wintermeyer P, Center P, Gehring S et al. Prevalence of hepatitis B virus precore stop codon mutations in chronically infected children. World J Gastroenterol 2006; 12: 2235-2238
452. Wismans P, van Hattum J, Stelling T ef al. Effect of supplementary vaccination in healthy non-responders to hepatitis B vaccination. Hepatogastroenterology 1988; 35: 78-79
453. Wit FW, Weverling GJ, Weel J et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186: 23-31
454. Wolters LM, van Nunen AB, Honkoop P et al. Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat 2000; 7: 428-434
455. Wong DK, Cheung AM, O'Rourke K et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-323
456. Wong DK, Yim C, Naylor CD et al. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology 1995; 108: 165-171
457. Wong VW, Chan HL, Wong ML et al. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. Aliment Pharmacol Ther 2004; 19: 323-329
458. World Health Organisation. Hepatitis Delta. Electronic Citation. 2001. http://www.who.int/csr/
459. World Health Organisation. Hepatitis B. Electronic Citation 2002. http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscsrlyo2002_2.pdf
460. Wursthorn K, Buggisch P, Lutgehetmann M et al. Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV. Antivir Ther 2006; 11: 647-652
461. Wursthorn K, Lutgehetmann M, Dandri M et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-684
462. Yang B, Zhang B, Xu Y et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 1997; 123: 357-360
463. Yang HI, Lu SN, Liaw YF et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174
464. Yao FY, Terrault NA, Freise C et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34: 411-416
465. Yeo W, Chan PK, Ho WM et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22: 927-934
466. Yeo W, Chan PK, Zhong S et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307
467. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-220
468. Yeo W, Steinberg JL, Tam JS et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 1999; 59: 263-269
469. Yeo W, Zee B, Zhong S et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-1311
470. Yu AS, Vierling JM, Colquhoun SD et al. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001; 7: 513-517
471. Yuen MF, Sablon E, Hui CK et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34: 785-791
472. Yurdaydin C, Bozkaya H, Gurel S et al. Famciclovir treatment of chronic delta hepatitis. J Hepatol 2002; 37: 266-271
473. Yurdaydin C, Wedemeyer H, Zachou K et al. A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus adefovir dipivoxil vs. pegylated interferon-alfa-2a plus placebo vs. adefovir dipivoxil for the treatment of chronic delta hepatitis. Hepatology 2006; 44: 230A
474. Zanetti AR, Mariano A, Romano L et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366: 1379-1384
475. Zarski JP, Bohn B, Bastie A et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998; 28: 27-33
476. Zavaglia C, Severini R, Tinelli C et al. A randomized, controlled study of thymosin-alphal therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B. Dig Dis Sci 2000; 45: 690-696
477. Zignego AL, Fontana R, Puliti S et al. Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. Arch Virol 1997; 142: 535-544
478. Zollner B, Schafer P, Feucht HH et al. Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. J Med Virol 2001; 65: 659-663
479. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005; 42: 302-308
480. Zuccotti GV, Cucchi C, Gracchi V et al. A 1-year trial of lamivudine for chronic hepatitis B in children. J Int Med Res 2002; 30: 200-202
481. Zylberberg H, Jiang J, Pialoux G et al. Alpha-interferon for chronic active hepatitis B in human immunodeficiency virus-infected patients. Gastroenterol Clin Biol 1996; 20: 968-971